Novo Nordisk - Regulatory Approval (December 2025): FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill-which launched in January 2026 [3]
Of note, although GLP-1GIPLani solidly outperforms GLP-1GIP co-agonism or semaglutide to yield greater decreases of body weight, food intake and hyperglycaemia, it induces equal amounts of FOS neuronal activation in the brainstem and hypothalamus (Fig
A personal or family history of medullary thyroid carcinoma rules you out
Definitely planning to reorder. Peptides Quality Ive ordered multiple peptides from Limitless Biotech over the past year
Substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), cardiometabolic disorders, chronic kidney disease, COPD, pneumonia, liver failure, inflammatory bowel disease, liver cancer) all significantly declined
Being monitored by a clinician throughout treatment should be a priority